Dupixent Clears Phase III in Bid to Become First Biologic for COPD

Sanofi and Regeneron’s Dupixent (dupilumab) met its primary and all secondary endpoints in the Phase III BOREAS trial, significantly reducing severe exacerbations in COPD.